Latest Eastbridge study shows continued focus on wellness benefits in voluntary coverage
AVON, Conn., April 22, 2025 /PRNewswire/ -- Virtually all voluntary carriers offer a wellness benefit with at least one of their products, almost always as an optional benefit rather than embedded into their products, according to a new study from Eastbridge Consulting Group. Eastbridge's "Voluntary Wellness Benefits" Frontline™ Report shows accident, critical illness or hospital indemnity plans are the most likely to include a wellness benefit.
"Carriers are expanding the wellness tests they cover with new screenings and preventive exams, and many take extra steps to encourage employees to take advantage of them," said Ginger Bates, Eastbridge director of research. "About half of carriers continue to promote these benefits even after the enrollment with customizable communication campaigns."
The "Voluntary Wellness Benefits" Frontline™ Report identifies and benchmarks the wellness benefits carriers offer with voluntary products and the trends for wellness benefits in the voluntary/worksite market. It includes data collected in January and February 2025 from 41 carriers providing 42 responses. Carriers can use this information to compare their offerings to competitors active in the market and evaluate opportunities to become more successful.
Other key findings in the report include:
Employee use of wellness benefits varies widely, but averages 20% for carriers that track this information.
Very few carriers require waiting periods or require insureds to incur a charge before paying wellness benefit claims.
All carriers that track loss ratios for their wellness benefits say they are as expected or lower than expected. None say they are higher than expected.
The "Voluntary Wellness Benefits" Frontline™ Report and other Frontline™ reports are available exclusively to survey participants and members of Eastbridge's Information Partner™ program. For information on the program or to participate in future Frontline™ report surveys, contact Eastbridge at info@eastbridge.com.
About Eastbridge Consulting GroupEastbridge Consulting Group, Inc. is a marketing advisory firm serving companies focused on the voluntary/worksite benefits market in the United States and Canada. Follow Eastbridge on LinkedIn at https://www.linkedin.com/company/eastbridge-consulting-group.
CONTACT: Ginger BatesEMAIL: gbates@eastbridge.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/latest-eastbridge-study-shows-continued-focus-on-wellness-benefits-in-voluntary-coverage-302433479.html
SOURCE Eastbridge Consulting Group
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
20 minutes ago
- Business Wire
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2025 financial results and highlighted recent corporate updates. 'In the first half of 2025, we made significant progress in our NGN-401 program for Rett syndrome. We completed dosing of the last five participants in the Phase 1/2 trial and received written agreement from the U.S. FDA on the key elements of the Embolden™ registrational trial, in which we have already begun initiation activities,' stated Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene. 'We are pleased to be moving forward with Embolden, which was purposefully and rigorously designed to differentiate NGN-401 by evaluating participants as young as three years of age with a primary endpoint that incorporates measures that KOLs, caregivers and payors believe to be clinically meaningful. Our previously announced reallocation of capital provides us runway into early 2028, enabling us to focus our resources on advancement of this potential therapy for the patients and families who urgently need new treatment options.' Dr. McMinn continued, 'In leveraging the continual dialogue under the START program, the FDA encouraged the analysis of the Embolden primary endpoint to remain at 12 months as the basis for full approval, noting that a 6-month endpoint may not be considered clinically meaningful. In further maintaining the rigorous design of the Embolden trial, we are electing to dose the last planned participant from the Phase 1/2 trial as part of the registrational Embolden trial and add one more participant to complete the proposed sample size at 20 patients.' Second Quarter 2025 and Recent Highlights, and Anticipated Milestones NGN-401 Gene Therapy for Treatment of Rett Syndrome Received written agreement from the U.S. Food and Drug Administration (FDA) on key elements of the Embolden registrational trial of NGN-401 and refined the sample size to propose 20 participants Initiated Embolden clinical trial activities to support the conversion of the Phase 1/2 trial to a registrational trial Completed enrollment in the Phase 1/2 trial, with the last 5 additional participants dosed in the first half of 2025 Remains on track to report updated clinical efficacy and safety data from the Phase 1/2 trial in the second half of 2025 Presented at scientific conferences the hemophagocytic lymphohistiocytosis (HLH) monitoring and treatment algorithm incorporated into the NGN-401 clinical trial, which has been acknowledged as valuable information by the Rett syndrome and gene therapy communities There has been no evidence of HLH/hyperinflammatory syndrome in any NGN-401 trial participant at the 1E15 vg dose level, as of the date of this press release Upcoming Events Stifel Biotech Summer Summit: Management will participate in a fireside chat at 12:00 p.m. ET on August 12 (not webcast) H.C. Wainwright Annual Global Investment Conference: Management will participate in a fireside chat at 2:30 p.m. ET on September 8 and participate in 1x1 meetings Second Quarter 2025 Financial Results Cash, Cash Equivalents and Short-Term Investments: Cash, cash equivalents and short-term investments as of June 30, 2025 were $274.5 million. We currently expect cash, cash equivalents and short-term investments to fund planned operations into early 2028. Research & Development (R&D) Expenses: R&D expenses were $19.4 million for the three months June 30, 2025 compared to $15.7 million for the three months ended June 30, 2024. The increase in R&D expenses for the three months ended June 30, 2025 was primarily driven by an increase in Rett syndrome clinical trial costs and employee-related expenses due to an increase in R&D headcount. General & Administrative (G&A) Expenses: G&A expenses were $6.7 million for the three months ended June 30, 2025 compared to $5.3 million for the three months ended June 30, 2024. The increase in G&A expenses for the three months ended June 30, 2025 was primarily driven by an increase in employee-related expenses due to an increase in stock-based compensation, headcount and other corporate expenses. Net Loss: Net loss was $22.0 million for the three months ended June 30, 2025 compared to $18.5 million for the three months ended June 30, 2024. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit About NGN-401 NGN-401 is an investigational AAV9 gene therapy being developed as a one-time treatment for Rett syndrome. It is the first clinical candidate to deliver the full-length human MECP2 gene under the control of Neurogene's EXACT™ transgene regulation technology. EXACT technology is an important advancement in gene therapy for Rett syndrome, specifically because the disorder requires a treatment approach that enables targeted levels of MECP2 transgene expression without causing overexpression-related toxic effects associated with conventional gene therapy. NGN-401 was selected by the U.S. Food and Drug Administration (FDA) for its START Pilot Program and has also received Regenerative Medicine Advance Therapy (RMAT) designation, orphan drug designation, Fast Track designation and rare pediatric designation from the FDA. Neurogene was previously granted an INTERACT meeting with the FDA regarding the EXACT technology. NGN-401 also received Priority Medicines (PRIME) designation, orphan designation and advanced therapy medicinal product designation from the European Medicines Agency (EMA) and the Innovative Licensing and Application Pathway (ILAP) designation from the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA). Cautionary Note Regarding Forward-Looking Statements Statements in this press release are made as of the date of this press release. Neurogene does not undertake any obligation to make any updates to these statements to reflect events that occur or circumstances that arise after the date of this press release, except as may be required under applicable U.S. securities law. Statements in this press release which are not historical in nature are intended to be, and hereby are identified as, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current expectations and beliefs of the management of Neurogene, as well as assumptions made by, and information currently available to, management of Neurogene, including, but not limited to, statements regarding: the therapeutic potential and utility, efficacy and clinical benefits of NGN-401; trial designs, clinical development plans and timing for NGN-401, including elements of the registrational clinical study trial design subject to final approval of the FDA, such as the proposed number of participants in the Embolden trial, and the timing of the conversion of the NGN-401 Phase 1/2 clinical trial to a registrational clinical trial, anticipated timing of additional updates for the Embolden registrational trial of NGN-401 for Rett syndrome; expected timing for additional interim data from the Company's NGN-401 Phase 1/2 trial for Rett Syndrome, expected future interactions with or positions of the FDA; and the time period over which existing cash resources may be sufficient to fund the Company's operations. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'should,' 'would,' 'expect,' 'anticipate,' 'plan,' 'likely,' 'believe,' 'estimate,' 'project,' 'intend,' 'on track,' and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Forward-looking statements are based on current beliefs and assumptions that are subject to risks, uncertainties and assumptions that are difficult to predict with regard to timing, extent, likelihood, and degree of occurrence, which could cause actual results to differ materially from anticipated results and many of which are outside of Neurogene's control. Such risks, uncertainties and assumptions include, among other things: the expected timing of additional results from the NGN-401 clinical trial; the potential for negative impacts to participants in the Phase 1/2 clinical trial of NGN-401 for the treatment of Rett syndrome; the risk that the Company may not be able to report data on the predicted timeline; risks related to the Company's ability to obtain regulatory approval for, and ultimately commercialize, its product candidates, including NGN-401; risks related to timing of initiating the Embolden trial of NGN-401 for Rett syndrome; and other risks and uncertainties identified under the heading "Risk Factors" included in Neurogene's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the Securities and Exchange Commission ('SEC') on August 11, 2025, and other filings that the Company has made and may make with the SEC in the future. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that the contemplated results of any such forward-looking statements will be achieved. Forward-looking statements in this communication speak only as of the day they are made and are qualified in their entirety by reference to the cautionary statements herein. Except as required by applicable law, Neurogene undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. This communication contains hyperlinks to information that is not deemed to be incorporated by reference into this communication. - Financial Tables Follow - Neurogene Inc. Condensed Consolidated Statements of Operations (In thousands of U.S. dollars, except share information) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenue under licensing agreements — 925 — 925 Operating expenses: Research and development expenses 19,366 15,744 37,131 29,285 General and administrative expenses 6,715 5,315 14,869 10,553 Total operating expenses 26,081 21,059 52,000 39,838 Loss from operations (26,081 ) (20,134 ) (52,000 ) (38,913 ) Other income, net 4,065 1,642 7,337 3,500 Net loss $ (22,016 ) $ (18,492 ) $ (44,663 ) $ (35,413 ) Per share information: Net loss per share, basic and diluted $ (1.05 ) $ (1.09 ) $ (2.12 ) $ (2.09 ) Weighted-average shares of common stock outstanding, basic and diluted 21,055,378 16,941,524 16,922,630 Expand
Yahoo
3 hours ago
- Yahoo
FuturHealth Offers Users Complimentary Access to Apple Fitness+ for Movement and Motivation
SAN DIEGO, Aug. 11, 2025 /PRNewswire/ -- FuturHealth, a leading provider of personalized weight-loss solutions, today announced that it will bring Apple Fitness+, the award-winning fitness and wellness service that is welcoming to all, to members who are enrolled in a FuturHealth program at no additional cost. The offer gives FuturHealth users additional fitness tools to help them reach their goals. This offer underscores FuturHealth's commitment to empowering members with a comprehensive toolkit that supports sustainable, personalized weight loss journeys, whether with medication, nutrition, fitness, or a combination of all three. "Our top priority has always been to help people on a weight loss journey experience real, long-lasting results through holistic lifestyle changes and personalized support," said Luke Mahoney, co-founder and CEO of FuturHealth. "With this Fitness+ offer, users can tap into thousands of workouts and meditations—wherever and whenever they choose—at no extra cost." Fitness+ offers users access to thousands of workouts and meditations in 4K Ultra High Definition on iPhone, iPad and Apple TV, ranging from 5 to 45 minutes across 12 different types including Strength, HIIT, Treadmill, Rowing, Cycling, Yoga, and more. All it takes is an iPhone to get started— and with Apple Watch, users can unlock even more motivation through personalized, real-time metrics right onscreen. Fitness+ workouts feature energizing music playlists by today's top artists all led by a diverse and inclusive team of trainers that can be done anytime, anywhere. Fitness+ also offers inspiring audio experiences including Time to Walk and Time to Run. Users can access the Fitness+ offer by simply tapping on the Apple Fitness+ module on the home screen in the FuturHealth app. This announcement follows a series of significant milestones for the company. This year alone, FuturHealth launched Affirm's flexible payment options for members, partnered with Valisure to ensure the highest quality and safety standards for weight-loss medications, and released compelling efficacy data showing that combining the FuturHealth Program with weight-loss treatments significantly enhances weight loss outcomes compared to medication alone. For more information about FuturHealth's innovative approach, visit About FuturHealth:FuturHealth is your partner in weight loss, providing personalized guidance designed to work with your everyday life. Together with a team of doctors, dietitians, and weight-loss experts, we combine scientifically-proven medications with clinically-crafted, expertly-curated meals for quick, easy, effective, and affordable wins. Founded with a mission to create a holistic and personalized alternative to traditional, one-size-fits-all weight-loss solutions, we meet each person where they are on their unique journey, empowering them to confidently take control of their well-being at every step of the way. With a network of 350+ providers across 48 states, FuturHealth has transformed the lives of over 1.5 million patients and counting. In under a year, it has achieved an extraordinary 980% growth in active patients and facilitated over 6 billion online interactions. View original content to download multimedia: SOURCE FuturHealth
Business Wire
4 hours ago
- Business Wire
Elucid's PlaqueIQ ™ Image Analysis Software Now Covered by United Healthcare
BOSTON--(BUSINESS WIRE)-- Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, announced that United Healthcare has updated its cardiac imaging guidelines to fully align with recent recommendations from radiology benefit manager EviCore. United Healthcare's new guidelines now include coronary computed tomography angiography (CTA) plaque quantification (see page 520), specifically encompassing Elucid's PlaqueIQ™ technology. The coverage will apply to all United Healthcare plans beginning October 1, 2025. PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology. PlaqueIQ delivers automated quantification and classification of plaque morphology, and is uniquely capable of identifying and quantifying lipid rich necrotic core, a plaque type strongly linked with cardiovascular risk. 1,2 The software is designed to help physicians prioritize and personalize treatment based on actual coronary artery disease, rather than population-based risk. This technology supports physicians in evaluating treatment of patients' symptoms and risk of future cardiac events, such as heart attack and stroke, and enables the development of personalized care pathways informed by each patient's individual plaque characteristics. 'United Healthcare's new e guidelines further underscore the need for better tools to help clinicians get ahead of heart attack and stroke,' said Elucid CEO Kelly Huang, PhD. 'With its basis in CT Virtual Histology™, we believe that PlaqueIQ is poised to make a meaningful difference towards this goal.' United Healthcare's updated guidelines align with recently issued guidelines by radiology benefit manager EviCore. In addition to the recent coverage decision by United Healthcare, a new CMS rule went into effect on January 1, 2025, which doubled the amount paid to hospitals and outpatient clinics who perform cardiac CT scans from $175 to $357.13. This has allowed more hospitals, particularly those in non-urban areas, to be able to offer this service, reducing disparities in care. In late 2024, five of the seven Medicare Administrative Contractors (MACs) issued decisions to extend coverage of Elucid's PlaqueIQ, making it available to over 70 percent of eligible Medicare patients across the United States. The newly assigned Category I code for coronary plaque analysis, which goes into effect on January 1, 2026, complements the recent coverage decisions by United Healthcare and EviCore, allowing for expanded patient access and personalized treatment for patients with coronary artery disease (CAD). About Elucid Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ™ image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit
